Location: Germany. Berlin preferred; Baden-Württemberg, Bavaria, North Rhine-Westphalia also suitable. Regular travel to Berlin, Bonn and selected university-hospital/policy hubs expected.
Oxford Nanopore is seeking an experienced Government Affairs Consultant to lead our policy engagement and stakeholder strategy in Germany on a part-time consultancy basis. This is a unique opportunity for a well-connected health policy professional to help shape the environment for the adoption of innovative genomic technologies within one of Europe's most influential healthcare markets.
The successful consultant will bring deep knowledge of the German healthcare and policymaking landscape, with the ability to engage credibly across government, self-governance bodies, clinical networks, patient organisations and industry associations. Working closely with our Global and EMEA Government Affairs teams, you will help position Oxford Nanopore as a trusted partner in the development of genomic medicine, health-data infrastructure and future reimbursement pathways.
We are particularly interested in individuals who understand the intersection of healthcare policy, diagnostics, genomics and innovation, and who are motivated by the opportunity to support the integration of next-generation sequencing technologies into clinical practice across rare disease, oncology and pathogen genomics.
Essential
Desirable
Germany is an institution-led market where clinical adoption depends on validation, governance, and reimbursement systems rather than commercial access alone. This role is therefore critical to ensuring ONT is embedded within the structures that define long-term clinical scale.
Please note that no terminology in this advert is intended to discriminate on the grounds of a person's gender, marital status, race, religion, colour, age, disability or sexual orientation. Every candidate will be assessed only in accordance with their merits, qualifications and abilities to perform the duties of the job.
#LI-Remote
#LI-RS1
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Our goal is to enable the analysis of anything, anywhere, by anyone.
We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data.
We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.
Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide.
Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
